Renal dyslipidemia in patients on chronic haemodialysis;Renalna dislipidemija u bolesnika na kroničnoj hemodijalizi

Lijecnicki Vjesnik

Volumn 125, Issue 3-4, 2003, Pages 77-80

  Kovačić, Vedran ^a   Šain, Milenka ^b   Vukman, Valentina ^b  

^a Dom zdravlja   (Croatia)

^b NONE

Author keywords

Hyperlipidemia etiology; Kidney failure, chronic complications; Renal dialysis; Triglycerides blood

Indexed keywords

BICARBONATE; CARNITINE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; STATINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

APHERESIS; ATHEROSCLEROSIS; DIET THERAPY; DYSLIPIDEMIA; HEMODIALYSIS; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIPID METABOLISM; PHENOTYPE; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

HUMANS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 17044450193     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Parfrey PS, Harnett JD, Barre PE. The natural history of myocardial disease in dialysis patients. J Am Soc Nephrol 1991;2:2-12.
2. Held PJ, Port FK, Webb RL, Turenne MN, Wolfe RA, Holzman E i sur.: The USRDS 1994 Annual Data Report Am J Kidney Dis 1994;24:1-181.
3. Collins A, Ma J, Herzog C. Acute and chronic survival of dialysis patients with acute myocardial infarction. J Am Soc Nephrol 1996;7:1476.
4. Rostand SG, Brunzell JD, Cannon RO, Victor RG. Cardiovascular complications in renal failure. J Am Soc Nephrol 1991;2:1053-62.
5. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K i sur. Hiperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995;6:121-5.
6. Biesenbach G, Zazgornik J. Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. Diabetes Care 1996;19:625-8.
7. Kang SS, Wong PWK, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992;12:279-98.
8. Jourdheuil-Rahmani D, Rolland PH, Garcon D. Homocysteine induces synthesis and secretion of serine-elastase in isolated smooth muscle cells from human normal arteries. Ir J Med Sci 1995;15:164.
9. Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol. 1993;22:854-8.
10. Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM, Guillou J, Charpiot P, Bodard H, Ghiringhelli O, Calaf R, Luccioni R, Garcon D. Hyperhomocysteinemia induced vascular damage in the minipig. Circulation. 1995;91:1161-74.
11. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997;96:1745-9.
12. Bostom A, Shemin D, Verhoef P, Nadeau M, Jacques P, Selhub J i sur Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. Arterioscler Thromb 1997;17:2554-8.
13. Dierkes J, Domröe U, Ambrosch A, Bosselmann HP, Neumann KH, Luley C. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol 1999;51:108-15.
14. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49:147-52.
15. Ma KW, Greene EL, Raij L. Cardiovascular risc factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992; 19:505-13.
16. Senti M, Romero R, Pedro-Bottet J, Pelegri A, Nogues X, Rubies-Prat J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992;41:1394-9.
17. Joven J, Vilella E, Ahmad S, Cheung MC, Brunzell JD. Lipoprotein heterogenity in end-stage renal disease, Kidney Int 1993;43:410-8.
18. Oda H, Yorioka N, Okushin S, Nishida Y, Kushihata S, Ito T i sur. Remnant-like particles cholesterol may indicate atherogenic risk in patients on chronic hemodialysis. Nephron 1997;76:7-14.
19. Zambon S, Zambon A, Stabellini N, Tarroni G, Gilli P, Crepaldi G i sur. Lipoprotein abnormalities in hypertriglyceridemic patient on long-term haemodialysis. J Intern Med 1993;234:217-21.
20. Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H i sur. Lipoprotein abnormalities without hyperlipidemia in moderate renal insuffiency. Nephrol Dial Transplant 1994;9:1580-5.
21. Elisaf MS, Bairaktari HT, Tziallas CS, Germanos NK, Siamopoulos KC. Atherogenic lipid and lipoprotein parameters in hemodialysis patients. Dial Transplant 1995;24:642-60.
22. Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P. Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia. Miner Electrolyte Metab 1999;25:258-62.
23. Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y i sur. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1996;27(6):848-54.
24. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 1998;13:2833-41.
25. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 1992;41: 1653-61.
26. Havel RJ, Hamilton RL. Hepatocytic lipoprotein receptors and intracellular lipoprotein catabolism, Hepatology 1988;8:1689-704.
27. Querfeld U, Ong JM, Prehn J. Effects of cytokines on production of lipoprotein lipase in cultured human macrophages. J Lipid Res 1990;31:1379-86.
28. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 1991;57:401-10.
29. Sakurai T, Oka T, Hasegawa H, Igaki N, Miki S, Goto T. Comparison of lipids, apoproteins and associated enzyme activities between diabetic and nondiabetic endstage renal disease. Nephron 1992;61:409-14.
30. Kamanna VS, Kashyap ML, Pai R. Uremic serum subfraction inhibits apolipoprotein A-I production by human hepatoma cell line. J Am Soc Nephrol 1994;5:193-200.
31. Deckelbaum RJ, Granot E, Oschry Y, Rose L, Eisenberg S. Plasma triglyceride determines structure-composition in low- and high-density lipoproteins. Arterioslerosis 1984;4:225-31.
32. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996;27:84-91.
33. Keane WF. Lipids and kidney. Kidney Int 1994;46:910-20.
34. Sutherland W, Walker RJ, Ball MJ, Stapley S, Robertson MC. Oxidation of low-density lipoproteins from patients with renal failure or renal transplants. Kidney Int 1995;48:227-36.
35. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G. Enhanced LDL oxidation in uremic patient an additional mechanism for accelerated atherosclerosis? Kidney Int 1994;45:876-83.
36. Reiner Z, Tedeschi-Reiner E. Pathophysiology of atherosclerosis. The morphology and developmental levels of atherosclerotic changes. Liječ Vjesn 1990;112:118-23.
37. Elisaf M, Bairaktari H, Tzallas C, Germanos N, Koulouridis E, Pappas M i sur. Lipid parameters including Lp(a) in hemodialysis patients. Renal Failure 1994;16:501-9.
38. Attman PO, Alaupovic P, Tavella M, Knight-Gibson C. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 1996;11:63-9.
39. Cressman MD, Heyaka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992;86:475-82.
40. Kandoussi AM, Hugue V, Cachera C, Hazzan M, Dracon M, Tacquet A i sur. Apo(a) phenotypes and Lp(a) concentrations in renal transplant patients. Nephron 1998;80(2):183-7.
41. Panzetta O, Cominacini L, Garbin U, Fratta Pasini A, Gammaro L, Bianco F i sur. Increased susceptibility of LDL to in vitro oxidation in patients on maintence hemodialysis: Effect of fish oil and vitamin E. Clin Nephrol 1995;44:303-9.
42. Bartens W, Wanner C. Lipoprotein(a): New insights into an atherogenic lipoprotein. Clin Invest 1994;72:558-67.
43. Walker RJ, Sutherland WHF, Walker HL, MacMahon S, Robson RA. Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. Nephrol Dial Transplant 1997;12(1):87-92.
44. Gehr TWB, Sica DA, Slugg PH, Hammett JL, Raymond R, Ford NF. The pharmacokinetics of pravastatin in patients on chronic hemodialysis. Eur J Clin Pharmacol 1997;53(2):117-21.
45. Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T i sur. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clin Nephrol 1995;43:268-77.
46. Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H i sur. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insuffiency. A controled study in human chronic renal disease. Nephron 1997; 75:286-94.
47. Nishikawa O, Mune M, Miyano M, Nishide T, Nishide T, Maeda A i sur. Effect of simvastatin on lipid profile of hemodialysis patients, Kidney Int Suppl 1999;71:219-21.
48. Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK. Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure. Clin Nephrol 1996;45(6):386-9.
49. Elisaf M, Bairaktari E, Kaptopodis P, Pappas M, Sferopoulos G, Tziallas C i sur. Effect of L-carnitine supplementation on lipid parameters in hemodialysis patients. Am J Nephrol 1998;18:416-21.
50. Vlassopoulos D, Noussias C, Hadjipetrou A, Arvantis D, Logothetis E, Magana P i sur. Long term effect of low molecular weight heparin on serum lipids in hypertrigliceridemic chronic hemodialysis patients, J Nephrol 1997;10:111-4.
51. Leu JG, Liou HH, Wu SC, Yang WC, Huang TP. Low molecular weight heparin in diabetic and nondiabetic hypercholesterolemic patients receiving long term hemodialysis. J Formos Med Assoc 1998;97:49-54.
52. Sperschneider H, Deppisch R, Beck W, Wolf H, Stein G. Impact of membrane choice and blood flow pattern on coagulation and heparin requirement-potential consequences on lipid concentrations. Nephrol Dial Transplant 1997;12(12):2638-46.
53. Mak RH. Effect ofmetabolic acidosis on hyperlipidemia in uremia. Pediatr Nephrol 1999;13:891-3.
54. Bonnefont-Rousselot D, Lehman E, Jaudon MC, Delattre J, Perrone B, Rechke JP. Blood oxidative stress and lipoprotein oxidizability in haemodialysis patients: effect of the use of vitamin E-coated dialysis membrane. Nephrol Dial Transplant 2000;15:2020-8.
55. Seres DS, Strein GW, Hashim S, Goldberg IJ, Levin NW. Improvement in lipoprotein profiles during high flux dialysis. J Am Soc Nephrol 1993;3: 1409-15.
56. Josephson MA, Pellner SK, Dasisgupta A. Improved lipid profiles in patient undergoing high flux dialysis. Am J Kidney Dis 1992;20:361-6.
57. Blankestijn PJ. Hemodialysis using high flux membranes improves lipid profiles. Clin Nephrol 1994;42:48-51.
58. Goldberg IJ, Kaufman AM, Lavarias VA, Vann-Reyes T, Levin NW. High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease. Nephrol Dial Transplant 1996;11:104-7.
59. Crawfor GA, Mahony JF, Stewart JH. Impaired lipoprotein lipase activation by uraemic and posttransplant sera. Clin Sci 1981;60:73-80.
60. Fishbane S, Bucala R, Pereira B. Founds H, Vlassara H. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivates in uremia. Kidney Int 1997;52:1645-50.
61. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM i sur. Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet 1994;343:1519-22.
62. Ingram AJ, Parbtani A, Churcill DN. Effects of two low-flux celulose acetate dialysers on plasma lipids and lipoproteins - A cross-over trial. Nephrol Dial Transplant 1998;13:1452-7.
63. Horkko S, Huttunen K, Laara E, Kervinen K, Kesaniemi YA. Effects of three treatment modes on plasma lipids and lipoproteins in uraemic patients. Ann Med 1994;26(4):271-82.
64. Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein P, Mittman N. The uremic dyslipidemia: A cross-sectional and longitudinal study. Am J Kidney Dis 1992;20(4);324-35.
65. Allegra V, Martimbianco L, Vasile A. Lipid and apolipoprotein patterns during erythropoietin therapy: Roles of erythropoietin, route of administration, and diet. Nephrol Dial Transplant 1997;12(5):924-32.
66. Prata MM, Madeira C, Vicente O, Miguel MJP. Lipid profile in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplan 1998;13(9):2345-7.
67. Turk Z, Mrzljak V, Turk N, Metelko Z. Changes of autoantibodies against oxidatively modified low density lipoproteins during long-term LDL-apheresis. Diabetes Nutr Metab 1999;12(6):413-7.